Study on Pivot-Point Vibration of Molecular Bond-Rupture Events by Quartz Crystal Microbalance for Biomedical DiagnosticsMolecular bond-rupture scanning is an effective method for the measurement of the energy level necessary to break a bond and distinguishing specific and nonspecific binding of biological molecules.
FDA Approves Gen-Probe's PROGENSA® PCA3 AssayCompany reveals first molecular test to help determine the need for repeat prostate biopsies in men who have had a previous negative biopsy.
Aria Announces Publication of Independent Study in the American Journal of Obstetrics & Gynecology Using Aria's TechnologyStudy, which exclusively examines women in their first trimester of pregnancy, provides largest data set to date for trisomy 18 pregnancies.
Pinpoint Genomics Announces Publication of Clinical Study Results in Lung CancerThe Pinpoint Dx Lung(TM) Assay is a molecular diagnostic assay that assesses the likelihood of death after lung cancer surgery.
OGT Releases New Whitepaper for Aiding Biomarker DiscoveryThe new document explores the need for biomarkers as indicators of disease, and discusses the vast potential of autoantibodies as markers of early disease development.
Ambry Genetics Reports Results from Clinical Diagnostic Exome™ Testing of Three PatientsThree individuals suffering from symptoms for which the cause could not be identified were successfully diagnosed. The findings are believed to mark the first of their kind in industry, with additional information to be released in the coming weeks.
La Jolla Pharmaceutical Company Acquires GCS-100The first-in-class clinical-stage compound inhibits Galectin-3, implicated in cancer and chronic organ failure.
Myriad Genetics Acquires Exclusive Rights to RAD51C Cancer GeneMutations in the RAD51C gene have been linked to an increased risk for developing hereditary breast and ovarian cancers.
Roche’s Novel Tests for the Management of Hepatitis C Virus Infection Receive CE MarkThe tests detect HCV RNA, which is a crucial marker in the management of hepatitis C infection.
Miraculins Files with Health Canada for PreVu Medical Device LicenseThe medical diagnostic company announced that it has filed a class II medical device license application with Health Canada for the PreVu Non-Invasive Skin Cholesterol Point of Care (POC) Test.
